Baxter International Inc., the U.S. maker of blood products and intravenous drugs, agreed to buy Swedish kidney-dialysis competitor Gambro AB for $2.8 billion to expand its dialysis-equipment business.
Gambro had about $1.6 billion in sales last year, Deerfield, Illinois-based Baxter said today in a statement. Gambro is jointly controlled by Sweden’s EQT Partners AB and Investor AB, the investment firm controlled by Sweden’s billionaire Wallenberg family. Including net debt, the deal is valued at $40.2 billion, Gambro said in a statement.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
